Patents Examined by Nianxiang (Nick) Zou
-
Patent number: 9994859Abstract: The present invention relates to a method of producing HPV pseudovirions in plant cells, the plant produced pseudovirions per se, a neutralization assay using the plant produced pseudovirions and pharmaceutical compositions comprising the plant produced pseudovirions.Type: GrantFiled: July 25, 2014Date of Patent: June 12, 2018Assignee: University of Cape TownInventors: Edward P Rybicki, Inga Isabel Hitzeroth
-
Patent number: 9868762Abstract: The invention relates to a method for purifying compositions containing virus-like particles (VLP), wherein a VLP-containing composition is filtered through a filter medium, in particular through a membrane, having a molecular weight cut off (MWCO) of more than 30 kDa, and the cell culture supernatant of VLP-expressing cells is used as a VLP-containing composition. The invention further relates to a VLP-containing composition which can be produced by this method.Type: GrantFiled: August 1, 2012Date of Patent: January 16, 2018Assignee: LIFE SCIENCE INKUBATOR BETRIEBS GMBH & CO. KGInventors: Victoria Demina, Heiko Manninga
-
Patent number: 9821054Abstract: A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.Type: GrantFiled: March 9, 2012Date of Patent: November 21, 2017Assignee: Turnstone Limited PartnershipInventors: Byram Bridle, Brian Lichty, Yonghong Wan, Jean-Simon Diallo, Chantal Lemay, John Bell
-
Patent number: 9790256Abstract: Provided is designer nucleic acid constructs and polypeptides that can be used as therapeutic vaccines against HPV18 and/or HPV16.Type: GrantFiled: August 19, 2016Date of Patent: October 17, 2017Assignee: JANSSEN VACCINES & PREVENTION B.V.Inventors: Evelien Margaretha Bunnik, Jerome Hubertina Henricus Victor Custers, Gerrit Christiaan Scheper, Koen Oosterhuis, Taco Gilles Uil, Selina Khan
-
Patent number: 9782473Abstract: Disclosed are yeast-based immunotherapeutic compositions, human immunodeficiency virus (HIV) antigens, and fusion proteins for the treatment and/or prevention of HIV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HIV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HIV and/or symptoms thereof.Type: GrantFiled: March 26, 2014Date of Patent: October 10, 2017Assignee: GLOBEIMMUNE, INC.Inventors: Thomas H. King, David Apelian
-
Patent number: 9783788Abstract: The present invention relates to the technical field of porcine pseudorabies virus, and more particularly to a porcine pseudorabies virus (PRV)-YF strain, with the preservation No. of CCTCC No. V201502. The present invention also provides an application of the porcine pseudorabies virus (PRV)-YF strain in preparing an inactivated vaccine of the porcine pseudorabies virus, the inactivated vaccine of the porcine pseudorabies virus and a preparation method thereof. It is proved through an immune efficacy evaluating test and a safety test that the inactivated vaccine of the porcine pseudorabies virus has good immune protective efficacy and is safe for weaned piglets, replacement gilts, pregnant sows and the like.Type: GrantFiled: January 31, 2016Date of Patent: October 10, 2017Assignees: Zhaoqing Dahuanong Biological Medicine Co., Ltd, South China Agricultural UniversityInventors: Ruiai Chen, Hongliang Huang, Changbao Ren, Xiaoyu Xie, Zheng She, Xuanzi Zhan, Xiaoxiong Deng, Manhua Tang
-
Patent number: 9738691Abstract: Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection.Type: GrantFiled: March 1, 2016Date of Patent: August 22, 2017Assignees: XIAMEN UNIVERSITY, XIAMEN INNOVAX BIOTECH CO., LTD.Inventors: Shaowei Li, Minxi Wei, Xianglin Kong, Yingbin Wang, Jun Zhang, Ningshao Xia
-
Patent number: 9732358Abstract: The present invention includes the Paramyxovirus Parainfluenza Virus 5 (PIV5) as an oncolytic agent for treating various cancers, including, but not limited to breast cancer, lung cancer and melanoma. PIV5 oncolytic agents include both wild type PIV5 and various recombinant PIV5 constructs. Recombinant PIV5 constructs may include PIV5 lacking the conserved C-terminus of the V protein (PIV5VAC), PIV5 with mutations in the N-terminus of the V/P protein (PIV5CPI?), and PIV5 expressing MDA-7/IL-24 (rPIV5-MDA7), rPIV5-V/P-CPI?, rPIV5-CPI+, rPIV-Rev, rPIV5-RL, rPIV5-P-S157A, rPIV5-P-S308A, rPIV5-L-A1981D, rPIV5-F-S443P, rPIV5-MDA7, rPIV5ASH-CPI?, or rPIV5ASH-Rev. Also included are methods of making and using such oncolytic agents and compositions including such oncolytic agents.Type: GrantFiled: January 24, 2013Date of Patent: August 15, 2017Assignee: University of Georgia Research Foundation, Inc.Inventor: Biao He
-
Patent number: 9707285Abstract: In one aspect, a method of treating cancer in a mammal is provided. The method comprises administering to the mammal an oncolytic vector that expresses a tumor antigen to which the mammal has a pre-existing immunity. In another aspect, a method of boosting immune response in a mammal having a pre-existing immunity to an antigen is provided comprising intravenous administration to the mammal of a B-cell infecting vector that expresses the antigen.Type: GrantFiled: March 16, 2010Date of Patent: July 18, 2017Assignee: Turnstone Limited PartnershipInventors: Brian Lichty, Byram Bridle, Yonghong Wan, Jonathan Bramson
-
Patent number: 9676819Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.Type: GrantFiled: September 22, 2011Date of Patent: June 13, 2017Assignee: INNAVAC PTY LTDInventors: David Charles Jackson, Amabel Tan, Weiguang Zeng
-
Patent number: 9642906Abstract: Embodiments of the disclosure concern methods and compositions for immunotherapy for human papillomavirus infection and diseases associated therewith. In specific embodiments, methods concern production of immune cells that target one or more antigens of HPV16 and/or HPV18, including methods with stimulation steps that employ IL-7 and IL-15, but not IL-6 and/or IL-12. Other specific embodiments utilize stimulations in the presence of certain cells, such as costimulatory cells and certain antigen presenting cells.Type: GrantFiled: October 21, 2016Date of Patent: May 9, 2017Assignee: Baylor College of MedicineInventors: Carlos A. Ramos, Cliona M. Rooney, Neeharika Narala
-
Patent number: 8343748Abstract: Recombinant truncated human furin was expressed in CHO cells and concentrated approximately 50-fold by ultrafiltration and diafiltration. The concentrate was purified by column chromatography on CAPTO MMC™ (mixed cation exchange/hydrophobic interaction gel) resulting in a 30-50 fold purification factor and a yield of at least 60%. The at least 20% pure preparation obtained after CAPTO MMC™ (mixed cation exchange/hydrophobic interaction gel) chromatography had already a purification degree allowing on-column maturation of pro-VWF. Then an additional Arginine Sepharose chromatography purification was carried out. This two column process for purification of truncated human furin resulted in an almost pure furin preparation with a specific activity of approximately 290,000 U furin/mg protein and a yield of about 50%.Type: GrantFiled: May 21, 2008Date of Patent: January 1, 2013Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Peter Matthiessen, Stefan Romeder-Finger, Peter Turecek, Hans-Peter Schwarz